ERBB2 and non-small cell lung carcinoma: ChiCTR1800020262 trial suggested that the 6-month incidence of PFS in HER2-amplified advanced NSCLC patients treated with pyrotinib is 51.9% (95%CI 34.0%- 69.3%).